Sam Gattis

Director at OerthBio, father of 3, biochemist, runner

[Oerth Bio @OerthBio]

Big thank you to @BattlefieldLead and Colonel Kevin Farrell for an enriching workshop. Who knew long-ago decisions on the battlefield could have such relevance today?

#leadershipmatters #oerthlings

[Keith Hornberger @KRHornberger]

Interesting: label recombinant E3s on Cys w/ maleimide + linker + target binder, electroporate into cells, see if degradation ensues. Complementary to covalent fragment screens. Eye-opener was that a tagged CRL adaptor (SKP1) also led to degradation.
https://t.co/ZcnvhKG1hA

[Antonio Regalado @antonioregalado]

SCOOP: An insanely well-funded company called Altos Labs is going after "rejuvenation" technology.

Yamanaka factors. Epigenetic clocks. CRISPR.

Offering academics $1 million salaries and more.

Investor rumor mill: Milner, Bezos, ARCH. Musk?

https://t.co/VMxxtA0fMO

[Dan Nomura @DanNomura]

Our new review out on the Ligandability of E3 Ligases for Targeted Protein Degradation Applications by ⁦@bridgetbelcher⁩ & ⁦@carlcward⁩ in ⁦@BiochemistryACS⁩ that includes our aggregate chemoproteomic data for cysteines in E3 ligases! https://t.co/t0WnYYBzT0

[bioRxiv @biorxivpreprint]

Assessing target engagement using proteome-wide solvent shift assays https://t.co/2rlX2AxCLm #bioRxiv